AI Article Synopsis
- A study analyzed the costs and impacts of starting or delaying ofatumumab treatment for relapsing-remitting multiple sclerosis (MS) patients in Canada using a Markov cohort model over ten years.* -
- Ofatumumab showed better health outcomes, like fewer relapses and improved job productivity, while also lowering treatment-related costs compared to other high-efficacy MS therapies.* -
- The findings suggest that beginning treatment with ofatumumab sooner rather than later can lead to enhanced health benefits for newly diagnosed patients with active MS.*
Article Abstract
The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690431 | PMC |
| http://dx.doi.org/10.57264/cer-2022-0175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!